ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 1861

Efficacy of Non-pharmacological Interventions: A Systematic Review Informing the 2023 EULAR Recommendations for the Management of Fatigue in People with Inflammatory Rheumatic and Musculoskeletal Diseases

(1840–1861) Health Services Research Poster III

9:00AM-11:00AM: Abstract Number: 2156

Efficacy of Olokizumab in Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of a Study

(2141–2176) RA – Treatments Poster III

9:00AM-11:00AM: Abstract Number: 2000

Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study

(1996–2018) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 1836

Embracing a Biopsychosocial Approach to Fibromyalgia-like Symptoms in People with SLE: Insights from the Type 2 SLE Consortium

(1827–1839) Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 2028

Endorsement of Core Domain Definitions to Measure the Impact of Glucocorticoids in Patients with Rheumatic Diseases: A Report from the OMERACT Working Group on Glucocorticoid Impact

(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 1717

Endothelial Cell Sphingosine 1-Phophate Receptor 1 Restrains VE-cadherin Cleavage and Attenuates Experimental Inflammatory Arthritis

(1713–1733) RA – Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2084

Enhancing Internal Medicine Curriculum: Key Rheumatology Themes in Inpatient Setting

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 2309

Enterococcus Gallinarum Prevalence in Patients with Systemic Lupus Erythematosus

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2376

Eosinophil Activation as a Biomarker for Discriminating Active and Remission Phase in ANCA-Associated Vasculitis

(2370–2386) Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes

9:00AM-11:00AM: Abstract Number: L04

EP-104IAR (Extended-Release Fluticasone Propionate for Injectable Suspension): Topline and Key Secondary Results from a Phase 2 Randomized, Double-blind, Vehicle-Controlled Trial in Subjects with Knee Osteoarthritis

Late-Breaking Abstract Poster

9:00AM-11:00AM: Abstract Number: 2391

Epidemiology and Predictors of Relapse in Giant Cell Arteritis: Results of the ARTESER Register

(2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

9:00AM-11:00AM: Abstract Number: 2281

Epidemiology and Risk of Brain Abscess in Patients with Systemic Lupus Erythematosus in Taiwan: A Nationwide Population-based Study

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2269

Evaluating Global Patterns in Treatment and Prevalence of Glucocorticoid Related Comorbidities in Systemic Lupus Erythematosus: An International Study

(2257–2325) SLE – Diagnosis, Manifestations, & Outcomes Poster III

9:00AM-11:00AM: Abstract Number: 2061

Evaluation of a Tool to Enhance Training of the Physical Examination of the Temporomandibular Joint (TM Joint) in Juvenile Idiopathic Arthritis (JIA)

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 1954

Evaluation of Cancer Screening Methods in Patients Diagnosed with Inflammatory Muscle Disease at Kansas University Medical Center

(1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].